Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Diamedica Therapeutics ( (DMAC) ).
DiaMedica Therapeutics has reported that, following an in-person pre-IND meeting with the U.S. Food and Drug Administration, regulators have requested one additional non-clinical 10-day modified embryo-fetal development and pre- and postnatal development study of its investigational therapy DM199 in a rabbit model for preeclampsia. The company has begun preparations for this required safety study and expects results by the second quarter of 2026, marking a key regulatory step that will influence the timing of its planned Phase 2 investigator-sponsored trial and could shape the future development path of DM199 in the preeclampsia indication.
The most recent analyst rating on (DMAC) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Diamedica Therapeutics stock, see the DMAC Stock Forecast page.
Spark’s Take on DMAC Stock
According to Spark, TipRanks’ AI Analyst, DMAC is a Neutral.
Diamedica Therapeutics faces significant financial hurdles with no revenue and rising net losses, leading to a low financial performance score. Technical analysis presents mixed signals, adding uncertainty. Despite this, the company’s optimistic guidance and significant progress in clinical trials offer some potential, reflected in a moderate earnings call score. However, the speculative nature of its valuation due to the absence of earnings and dividends remains a key risk.
To see Spark’s full report on DMAC stock, click here.
More about Diamedica Therapeutics
DiaMedica Therapeutics Inc., headquartered in Minneapolis and incorporated in British Columbia, is a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker DMAC. The company is focused on developing its lead drug candidate DM199 for serious conditions such as preeclampsia and acute ischemic stroke, targeting significant unmet medical needs in neurology and maternal health.
Average Trading Volume: 397,610
Technical Sentiment Signal: Buy
Current Market Cap: $456.2M
See more data about DMAC stock on TipRanks’ Stock Analysis page.